F-1/A: Cuprina Holdings Eyes Nasdaq with $15.9 Million IPO, Resale Offering by Key Shareholders

Cuprina Holdings, a Singapore-based biomedical firm, is set to launch its initial public offering on the Nasdaq, aiming to raise $15.9 million while also facilitating a resale offering by existing shareholders.

Summary

• Cuprina Holdings (Cayman) Limited is preparing for an initial public offering (IPO) of 3,750,000 Class A Ordinary Shares, with an expected price between $4.00 and $4.50 per share.
• The company has applied to list its Class A Ordinary Shares on the Nasdaq Capital Market under the ticker symbol CUPR.
• Concurrently, certain existing shareholders are offering 1,500,000 Class A Ordinary Shares in a resale offering.
• Cuprina Holdings will not receive any proceeds from the resale of shares by these shareholders.
• The company intends to use the net proceeds from the IPO for growth and expansion into new markets, research and development, building brand awareness, investment in equipment and infrastructure, and loan repayment.
• Cuprina Holdings is an emerging growth company and a foreign private issuer, which allows it to take advantage of reduced reporting requirements.
• The company's revenue for 2023 was S$100,773 (approximately US$76,424), and it recorded a net loss of S$1,119,555 (approximately US$849,048).
• The offering is subject to Nasdaq's final approval of the listing application.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the company has growth plans and innovative products, it also faces financial challenges and risks, resulting in a neutral sentiment score.

Positives

• The company has strategic plans to expand sales and establish physical operations in Southeast Asia, the Middle East, and mainland China.
• Cuprina Holdings has attained ISO 13485:2016 standards for its manufacturing facility in Singapore.
• The company is working towards obtaining compliance with 21 CFR Part 820 to secure FDA 510(k) clearance for its chronic wound care products.
• The company has access to innovative technology in developing pipeline products through collaborations with research universities.

Negatives

• The company has a history of losses and expects to incur losses in the future.
• The company recorded net current liabilities as of December 31, 2021, 2022 and 2023.
• The company had net operating cash outflows for the years ended December 31, 2021, 2022 and 2023.
• The company's independent registered public accounting firm expressed substantial doubt regarding its ability to continue as a going concern.

Risks

• An active trading market for the Class A Ordinary Shares may not be established.
• The trading price of the Class A Ordinary Shares may be volatile.
• The company may not maintain the listing of its Class A Ordinary Shares on the Nasdaq.
• The company's corporate actions are significantly influenced by its directors, officers, and principal shareholders.
• The dual-class structure of the company's ordinary shares may adversely affect the trading market for its Class A Ordinary Shares.
• The sale or availability for sale of substantial amounts of the company's Class A Ordinary Shares could adversely affect their market price.
• The company's ability to continue as a going concern requires that it obtain sufficient funding to finance its operations.
• The regulatory approval and clearance processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable.

Future Outlook

The company has strategic plans in place for the second half of 2024 and 2025 to expand sales and establish physical operations in Southeast Asia, the Middle East, and mainland China and plans to explore the possibility of developing a range of potential cosmeceutical product candidates incorporating bullfrog collagen with a view to making them commercially available between 2024 and 2028, subject to the progress of the relevant R&D work.

Industry Context

The company operates in the biomedical and biotechnology industry, focusing on chronic wound care and cosmeceuticals, which are experiencing growth due to an aging population and increased prevalence of comorbidities.

Comparison to Industry Standards

• The document does not provide enough information to make a detailed comparison to industry standards.
• However, the document mentions competitors such as Smith & Nephew plc, ConvaTec Group plc, Mlnlycke Health Care AB, 3M, Integra Urgo Group, which are all large, established players in the wound care market.
• Cuprina Holdings is a smaller, early-stage company compared to these competitors.

Related Party Transactions

• Cuprina Holding Pte. Ltd. provided advances to the company for working capital purposes.
• Jimmy Lee Peng Siew, an ultimate beneficial owner, provided advances to the company for working capital purposes.
• The company has entered into various joint venture agreements with local partners in countries like Saudi Arabia.
• The company has entered into a licensing agreement and an industry research collaboration agreement with NTU.

Stakeholder Impact

• Shareholders will experience dilution as a result of the IPO.
• The company's ability to execute its growth plans will impact its employees and suppliers.
• Customers may benefit from new and innovative products developed by the company.

Next Steps

• Obtain Nasdaq approval for listing.
• Execute expansion plans into new geographic markets.
• Continue research and development of pipeline products.
• Strengthen brand awareness and customer acquisition efforts.

Key Dates

Keywords

IPO, Cuprina Holdings, Class A Ordinary Shares, Nasdaq, Resale Offering, Wound Care, Biomedical, Biotechnology, MEDIFLY, Maggot Debridement Therapy, Collagen Dressings, Cosmeceuticals